Intelligence factory opportunity map
Regeneron Pharmaceuticals · Outside-in analysis · August 2026
Confidential — prepared for internal review only
- 78% of mapped decision points are automatable. Across 42 decision points in the four flagship workflows, 19 (45%) can run as deterministic edge functions at near-zero cost and 14 (33%) as generative API calls — leaving only 9 (22%) as irreducible human judgment nodes.
- Patient Services is the highest-value target. The PA/benefit verification workflow alone represents $13–56M in combined savings and revenue protection from reduced prescription abandonment across Dupixent MyWay, EYLEA4U, LIBTAYO Surround, and MyPRALUENT.
- Regeneron's AI is concentrated in R&D — commercial is the white space. The published AI policy confirms ML/NLP/LLM use in Global Development and the Genetics Center, but the six priority commercial/infrastructure departments have minimal disclosed AI deployment.
- Five permanent kill gates constrain the architecture. FDA promotional compliance (MLR), AKS/FCA (copay assistance — elevated by active DOJ litigation), SOX (financial attestation), hiring decisions (Regeneron's own AI policy), and government pricing certification cannot migrate to automation regardless of accuracy.
- The gap your current vendor misses is the task→decision→process hierarchy. Mapping roles and tasks is necessary but insufficient. The value unlock comes from connecting each task to the decision it serves, assigning that decision through the Jagged Edge Trilemma, and chaining decisions into agent assembly lines with guardian agents at every handoff.
What your current approach misses
Your vendor ingests role descriptions and proposes tasks with AI potential. This analysis goes three layers deeper: it maps every decision point within each workflow (not just the tasks), assigns each to the optimal intelligence layer through the Jagged Edge Trilemma (deterministic edge function vs generative API call vs human judgement), and designs the agent assembly line — the complete pipeline of specialized agents with guardian agents validating quality at every handoff. The result: you see not just what can be automated, but exactly how the automation chains together into end-to-end intelligent workflows.
Regeneron at a glance — Q2 2026
Financial and strategic signals that shape the automation opportunity
Friction signals from leadership
Q2 2026 earnings call surfaced: a temporary manufacturing disruption at Limerick that dented gross margin (78% vs 83%); FDA leadership changes creating regulatory uncertainty; the April 2026 MFN pricing agreement adding government-pricing complexity; and a DOJ False Claims Act case over copay-assistance donations. Each represents an information-processing burden that automation can address.
AI initiatives already underway
Regeneron's published Position Statement on Responsible Use of AI (July 2025) confirms company-wide use of ML, NLP, GPTs, LLMs, and RPA, governed by a cross-functional AI Advisory Committee. Disclosed deployments concentrate in Global Development and the Regeneron Genetics Center — not in the six priority commercial functions. Two hard internal kill gates already codified: AI is barred from final decisions on personnel hiring and financial decisions.
Peer benchmarks
Sanofi plai: 15,000+ daily users, 300+ AI models, predicted 80% of low inventory positions, ~$300M supply-chain savings, $800M reallocated per Fortune report. Eli Lilly/Yseop: eliminated 10,000 hours of clinical narrative writing, 53% third-party cost reduction. Veeva Falcon MLR: potential to "eliminate 70% or more of manual MLR labor within five years." Develop Health Calibrate: "80–85% reduction in PA volume." All figures are vendor/company claims and should be treated as directional.
Six priority departments — automation potential by function
Click any department to see its workflows. Star ratings indicate analysis depth available.
Four flagship workflows mapped at full depth
Each workflow mapped with the complete methodology: every decision point documented, assigned through the Jagged Edge Trilemma, and chained into an agent assembly line with guardian agents and trust escalation.
MLR content review — 11 decision points, 36% edge / 36% API / 28% human
Assembly line: Brief validator → Reference checker → Claims-to-label mapper → Fair balance analyzer → Pre-review synthesizer → Human: Legal/Reg/Medical review → Revision checker → Approval recorder → Expiration monitor
The human operator today
On any given Tuesday morning, a Medical Reviewer at Regeneron opens Veeva Vault PromoMats and finds fourteen items in queue. Three are Dupixent HCP detail aids for the new COPD indication. Two are EYLEA HD patient brochures for the pre-filled syringe launch. One is a Libtayo congress poster submitted Friday at 4:47 PM with a note reading "urgent — booth printing deadline Thursday."
The reviewer doesn't read these documents linearly. She scans for specific failure modes: every efficacy claim must trace to the approved prescribing information. Every comparative statement must be supported by head-to-head data. Fair balance — risk information presented with comparable prominence to benefits — must be adequate. No off-label promotion. A single piece may cycle three to five times before approval, and the ASCO poster will consume four hours across two reviewers while the brand team works past midnight.
The bottleneck isn't competence — it's the volume-to-reviewer ratio and the cognitive load of context-switching across 8+ brands, dozens of indications, and hundreds of approved claims that may have been updated by a supplemental approval since the last review cycle.
Decision-point map
| # | Decision point | Assignment | Inputs | Judgment | Output | Consequence |
|---|---|---|---|---|---|---|
| 1 | Content brief intake & completeness | Edge | Submitted asset, brief template | Checklist match — all fields present? | Accept or return to brand | Low — caught downstream |
| 2 | Reference verification | API | Claims text, cited sources, PI | Does each claim resolve to an approved source? | Citation map with flags | High — FDA Warning Letter |
| 3 | Claims-to-label mapping | API | Claims, current PI, prior approvals | Is every claim within approved labeling? | Mapped claims + off-label flags | Critical — off-label promotion, FCA |
| 4 | Fair balance assessment | Edge + API | Asset layout, risk/benefit text | Risk prominence ≥ benefit prominence? | Balance score + deficiency flags | High — OPDP letter |
| 5 | Competitive claims review | Human | Comparative statements, competitor data | Legal risk of each comparative claim | Approve / revise / escalate | High — Lanham Act complaint |
| 6 | Legal review | Human | Full asset, IP terms, co-promo agreements | IP exposure, contractual compliance | Legal sign-off or revision list | Medium-high — IP, co-promo terms |
| 7 | Regulatory review | Human + API | Full asset, FDA guidance, OPDP history | Regulatory risk across all claims | Regulatory sign-off or hold | Critical — regulatory non-compliance |
| 8 | Medical review (final) | Kill gate | Pre-screened asset + all prior reviews | Clinical accuracy, patient safety | Final approval or rejection | Critical — patient harm, FDA enforcement |
| 9 | Revision compliance check | API | Revised asset, revision comments | Were all requested changes implemented? | Compliance confirmation or re-route | Medium — additional cycle delay |
| 10 | Version control & approval recording | Edge | Approved asset, metadata | Correct version, correct status in Vault | Recorded approval + audit trail | Medium — compliance finding |
| 11 | Expiration & withdrawal monitoring | Edge + API | Approved assets, PI update feed, calendar | Has PI changed since approval? Is asset expiring? | Withdrawal alerts + re-review triggers | High — outdated content in circulation |
Guardian agents
Claims guardian
Validates every citation resolves to an approved PI section. Rejects any claim where the source is a poster, abstract, or non-peer-reviewed publication unless explicitly permitted by the approved claims matrix.
Fair balance guardian
Validates risk/benefit prominence ratio meets FDA standards (OPDP guidance). Measures text area, font size, and placement of risk information relative to efficacy claims. Flags any asset where risk prominence falls below 80% of benefit prominence.
Approval guardian
Validates all revision comments from Legal, Regulatory, and Medical reviewers are addressed before final recording. Cross-references comment log against revised asset. Blocks recording if any comment is unresolved.
Trust escalation ladder
Economics
Permanent kill gates
Medical review final sign-off — FDA 21 CFR 202.1 requires human physician sign-off on all promotional materials. No AI accuracy level removes this requirement.
Competitive claims review — Lanham Act litigation risk on comparative claims requires human legal judgment on case-by-case basis.
PA & benefit verification — 13 decision points, 46% edge / 31% API / 23% human
Assembly line: Case intake → Insurance verifier → Benefit investigator → PA pathway router → Clinical evidence assembler → PA form completer → Submitter → Status tracker → [Denied: Analyzer → Human: appeal decision] → Copay/PAP router → Human: eligibility check → Enrollment → Adherence monitor
The human operator today
A Patient Access Coordinator at Dupixent MyWay starts each morning with forty to sixty new cases. Each represents a patient whose physician has prescribed a ~$36,000/year biologic and who needs help navigating insurance coverage. The coordinator logs into payer portals, determines PA requirements (which vary by payer, plan, and indication across atopic dermatitis, asthma, COPD, CSU, and eosinophilic esophagitis), assembles clinical evidence packages, completes payer-specific PA forms, submits, and tracks status — calling payer phone lines that average 12–25 minutes of hold time per call.
If denied, the coordinator initiates appeals: peer-to-peer scheduling, additional documentation, formal appeal letters. Each adds 2–4 weeks. Industry data shows 30–40% of specialty prescriptions are abandoned during PA. Each abandoned Dupixent prescription is both a patient who doesn't receive therapy and approximately $36,000 in lost annual revenue.
Multiply across four hub programs — Dupixent MyWay (1.5M+ patients), EYLEA4U, LIBTAYO Surround, MyPRALUENT — and the operation processes thousands of cases monthly, each with its own payer rules, clinical requirements, and urgency level.
Decision-point map
| # | Decision point | Assignment | Inputs | Judgment | Output | Consequence |
|---|---|---|---|---|---|---|
| 1 | Case intake & triage | Edge | Prescription, patient demographics | Completeness check, priority scoring | Triaged case record | Low — incomplete data caught next step |
| 2 | Insurance verification | Edge | Member ID, payer info | Eligibility lookup against payer DB | Coverage status + plan details | Medium — wrong payer = wasted submission |
| 3 | Benefit investigation | API | Plan details, drug formulary data | PA required? Step therapy? Tier? | Coverage pathway map | High — missed PA = claim denial |
| 4 | PA pathway routing | Edge | Payer rules, indication, prior therapy | Which payer-specific PA form applies? | Routed to correct pathway | Medium — wrong form = rejection |
| 5 | Clinical evidence assembly | API | Patient chart, payer criteria, guidelines | Which evidence satisfies this payer? | Evidence package with citations | High — weak evidence = denial |
| 6 | PA form completion | API | Evidence package, payer form template | Map evidence to form fields accurately | Completed PA form | Medium — errors delay approval |
| 7 | Electronic submission | Edge | Completed form, portal credentials | Correct portal, correct format | Submission confirmation + tracking ID | Low — resubmit if rejected |
| 8 | Status tracking | Edge | Tracking IDs, response timelines | Overdue? Needs follow-up? | Status updates + escalation triggers | Medium — delayed = patient waiting |
| 9 | Denial analysis | API | Denial letter, payer criteria, history | Why denied? What would overturn? | Root cause + appeal options | High — missed appeal = abandoned Rx |
| 10 | Appeal strategy decision | Kill gate | Denial analysis, clinical context, urgency | Peer-to-peer? Written appeal? Escalate? | Appeal pathway selection | Critical — wrong strategy = permanent denial |
| 11 | Copay/PAP eligibility | Kill gate | Patient financials, program criteria, AKS rules | Qualifies without inducement risk? | Eligible / ineligible + assignment | Critical — AKS/FCA violation (active DOJ) |
| 12 | Enrollment processing | Edge | Eligibility determination, program rules | Correct program, correct copay card | Enrolled patient record | Low — administrative correction |
| 13 | Adherence monitoring | API | Refill data, appointment history | Risk of discontinuation? Intervene? | Adherence score + outreach triggers | High — non-adherence = lost patient |
Guardian agents
Clinical evidence guardian
Validates evidence package contains required diagnosis codes (ICD-10), lab values, and prior therapy documentation for the specific payer's criteria. Rejects incomplete packages before form completion.
Submission guardian
Validates all required fields populated, correct payer portal selected, patient consent on file, and form version matches current payer requirements.
Eligibility guardian
Validates AKS/FCA compliance on every copay assistance determination. Confirms no prohibited inducement patterns, checks against federal healthcare program enrollment.
Trust escalation ladder
Economics
Permanent kill gates
Copay/PAP eligibility determination — AKS/FCA prohibits AI from determining financial assistance eligibility. Active DOJ False Claims Act investigation elevates this to litigation defense.
Appeal strategy selection — Clinical judgment required for peer-to-peer vs written appeal vs external review for each patient's specific situation.
HIPAA consent management — Patient authorization for data sharing across hub programs requires informed consent.
Accounts payable — 9 decision points, 67% edge / 22% API / 11% human
Assembly line: Data capture → PO matcher → GRN matcher → HCP-spend screener → Duplicate detector → Approval router → Human: above threshold → Payment scheduler. Exception: Discrepancy resolver → Human adjustment
The human operator today
An AP Specialist opens Oracle Fusion each morning to a queue of invoices from hundreds of vendors: CROs billing millions for clinical trials, contract manufacturers for API production, marketing agencies for congress sponsorships, and freight companies for cold-chain biologics shipment. Each follows the same flow: capture, match against PO, match against goods receipt, resolve discrepancies, route for approval, schedule payment.
The friction is in exceptions — approximately 20–30% require handling. A CRO's invoice references a change order; a marketing agency includes out-of-scope travel. Layered on top: every payment that could constitute a "transfer of value" to an HCP must be tracked for Sunshine Act reporting. Given the DOJ/FCA matter, accuracy on HCP-spend tracking is a litigation defense requirement.
Decision-point map
| # | Decision point | Assignment | Inputs | Judgment | Output | Consequence |
|---|---|---|---|---|---|---|
| 1 | Invoice data capture | Edge | Invoice image/PDF | OCR extraction + field mapping | Structured invoice record | Low — manual correction available |
| 2 | PO matching | Edge | Invoice line items, PO database | Line-by-line match within tolerance | Matched / unmatched flags | Medium — delays payment |
| 3 | GRN matching | Edge | PO match, goods receipt records | Three-way match: PO + GRN + invoice | Clean match or discrepancy flag | Medium — overpayment risk |
| 4 | HCP-spend screening | Edge | Vendor record, NPI database, payment details | Is vendor an HCP? Is payment transfer of value? | Sunshine Act flag + categorization | Critical — DOJ/FCA defense |
| 5 | Duplicate detection | Edge | Invoice hash, historical payments | Submitted before? | Duplicate flag or clear | Medium — double payment |
| 6 | Discrepancy resolution | API | Unmatched items, PO terms, vendor history | Legitimate change or error? | Resolution recommendation | Medium-high — vendor relationship |
| 7 | Approval routing | Edge | Invoice amount, cost center, approval matrix | Who must approve per SOX matrix? | Routed to correct approver | High — SOX compliance violation |
| 8 | Payment authorization | Kill gate | Matched invoice, approval chain, amount | Authorize payment above SOX threshold | Authorized or held | Critical — SOX, financial decisions policy |
| 9 | Payment scheduling | Edge | Authorized invoices, payment terms | Optimal payment date within terms | Scheduled payment batch | Low — adjustable |
Guardian agents
Match guardian
Validates three-way match (PO/GRN/invoice) within defined tolerance (1-2% or $100). Rejects invoices where line-item variance exceeds tolerance before compliance screening.
Compliance guardian
Cross-references every payment against NPI database for Sunshine Act reporting. Confirms categorization (meals, travel, consulting, research) matches payment description. Flags ambiguous vendor-HCP relationships.
Threshold guardian
Validates payment amount against SOX approval matrix. Confirms correct approver(s) in routing chain based on amount, cost center, and vendor category. Blocks payments bypassing required approval levels.
Trust escalation ladder
Economics
Permanent kill gates
SOX payment authorization — Payments above threshold require human approval per internal control framework. External auditors rely on this control.
Regeneron AI policy — Explicitly bars AI from "financial decisions." Payment authorization is classified as a financial decision.
HCP-spend adjudication — Given active DOJ/FCA case, Sunshine Act compliance adjudication is a litigation defense function requiring human sign-off.
Talent acquisition — 9 decision points, 33% edge / 45% API / 22% human
Assembly line: JD optimizer → Sourcing strategist → Resume screener/ranker → Human: phone screen → Interview scheduler → Feedback synthesizer → Human: hire decision → Offer modeler → Background checker → Onboarding configurator
The human operator today
A TA Partner juggles twenty-five open requisitions: seven field sales roles for the COPD launch (cohort hiring for training classes), five manufacturing roles at the new $2B Saratoga Springs facility, four clinical operations, three RGC research positions, and assorted finance/IT/executive searches. With ~972 active postings (34.4% YoY increase), the volume pressure is real.
For Medical Specialist roles, she receives 80–150 applications per posting. First pass: 2–3 minutes per resume. She rejects 60–70% and advances the rest to phone screen. Phone screens take 20–30 minutes each. Then: interview coordination across panels, feedback synthesis, offer development, background checks, onboarding.
Decision-point map
| # | Decision point | Assignment | Inputs | Judgment | Output | Consequence |
|---|---|---|---|---|---|---|
| 1 | JD optimization | API | Hiring manager intake, role requirements | Inclusive language, SEO, positioning | Optimized job posting | Low — poor posting = fewer applicants |
| 2 | Sourcing strategy | API | Role type, talent market data, channels | Which channels produce best candidates? | Channel-prioritized sourcing plan | Medium — wrong channels = weak pipeline |
| 3 | Resume screening & ranking | API | Applications, JD criteria, hire profiles | Qualification fit, experience relevance | Ranked candidate list + rationale | High — false negatives lose top talent |
| 4 | Phone screen | Kill gate | Resume, role brief, availability | Communication, motivation, culture | Advance / reject + interview brief | High — relationship assessment |
| 5 | Interview scheduling | Edge | Panel availability, candidate preferences | Optimal time slot across constraints | Confirmed interview schedule | Low — reschedule if needed |
| 6 | Feedback synthesis | API | Interview scorecards, panel notes | Aggregate signal across interviewers | Synthesized assessment | Medium — poor synthesis = biased decisions |
| 7 | Hire decision | Kill gate | Assessment, headcount, comp band | Hire / no-hire / continue search | Hiring decision + justification | Critical — wrong hire costs 1.5–2× salary |
| 8 | Offer modeling | Edge + API | Comp band, market data, expectations | Base + equity + sign-on within policy | Draft offer for approval | Medium — uncompetitive = lost candidate |
| 9 | Background check & onboarding | Edge | Candidate data, vendor integration | Initiate checks, configure onboarding | Cleared candidate + Day 1 readiness | Low — standard process |
Guardian agents
Bias guardian
Validates no protected-class signals in ranking. Runs adverse impact analysis against the four-fifths rule (EEOC). Flags any ranking where a protected group's selection rate falls below 80% of the highest group's rate. Required for NYC LL144.
Completeness guardian
Validates all interview scorecards received before the assessment package is presented to the hiring manager. Blocks hire/no-hire until every scheduled interviewer has submitted structured feedback.
Compliance guardian
Validates offer within approved comp band, equity within policy limits, sign-on within budget authority. Confirms OFCCP compliance for federal contractor positions.
Trust escalation ladder
Economics
Permanent kill gates
Hire/no-hire decision — Regeneron AI policy explicitly bars AI from personnel hiring. EEOC guidance on automated employment decisions and NYC LL144 create additional regulatory constraints. Triple lock: policy + regulatory + legal.
Phone screen — Relationship assessment and cultural fit evaluation require human judgment. Candidate experience impacts offer acceptance and employer brand.
Offer negotiation — Compensation judgment at the individual level (equity weighting, sign-on structure, start date flexibility) requires human assessment.
15 intelligence stacks + 5 intelligence factories, ranked by value
Each assembly line maps a complete workflow — every layer, every data source, every kill gate. Scroll to explore all 15.
PA & benefit verification
Ingests patient/insurance data, predicts coverage, pre-populates PA forms, submits, tracks, and routes denials across four hub programs.
Receives prescription and patient demographics, validates completeness, assigns priority score
Looks up coverage status and plan details against payer eligibility databases
Determines PA requirements, step therapy, tier placement for the specific drug and indication
Selects the correct payer-specific PA form and criteria pathway
Compiles diagnosis codes, lab values, and prior therapy documentation matching payer criteria
Maps evidence package to payer form fields with correct formatting
Transmits completed form to the correct payer portal electronically
Monitors submission status, triggers follow-up on overdue responses
Parses denial letters, identifies root cause, generates appeal strategy options
Selects peer-to-peer, written appeal, or escalation based on clinical judgment
Determines which financial assistance program applies based on patient eligibility
Makes AKS/FCA-compliant eligibility determination — litigation defense function
Configures patient in the correct assistance program with appropriate copay card
Tracks refill patterns, appointment history, flags discontinuation risk
Submitted PA with clinical evidence
40–60 cases/day per coordinator → auto-submission for routine payers
MLR content pre-review
Auto-checks promotional content against approved claims, current PI, and prior MLR decisions before human review.
Checks content brief completeness against template requirements — all fields present or return to brand
Verifies every citation resolves to an approved primary source or PI section
Maps each efficacy claim against current prescribing information and approved claims matrix
Measures risk/benefit prominence ratio — text area, font size, placement of safety information
Produces consolidated review package highlighting issues for human reviewers
Three-person review committee applies clinical, legal, and regulatory judgment — permanent FDA requirement
Validates all reviewer comments addressed in the revised asset before re-routing
Records final approval status, version, and complete audit trail in Veeva Vault
Watches for PI updates, label changes, and asset expiration dates — triggers re-review
Pre-reviewed asset with flagged issues
Cycle time from 2–3 weeks to 3–5 days
Accounts payable automation
OCR capture through three-way match, HCP-spend screening, and payment scheduling in Oracle Fusion. Fastest beachhead.
OCR extraction from invoice PDF/image into structured fields — vendor, amount, PO reference, line items
Line-by-line match of invoice items against purchase order within defined tolerance
Three-way match: validates goods/services receipt confirms delivery before payment
Cross-references vendor against NPI database — flags any payment that could be a transfer of value to an HCP
Hashes invoice against historical payment records to prevent double-payment
Routes to correct approver(s) based on SOX approval matrix, amount, and cost center
Authorizes payment above SOX dollar threshold — required by internal control framework and AI policy
Optimizes payment timing within vendor terms to manage cash position
Analyzes unmatched items against PO change orders and vendor history — recommends resolution
Approves manual adjustments for exceptions that cannot be auto-resolved
Touchless invoice processing
67% edge functions — highest automation density of all 15
Resume screening & sourcing
Screens and ranks applicants for ~972 open reqs. Does NOT make hire/no-hire decisions — Regeneron policy bars this.
Rewrites job descriptions for inclusive language, SEO, and competitive positioning
Identifies highest-yield channels for each role type based on historical conversion data
Scores and ranks all applicants against JD criteria and historical hire profiles
Assesses communication skills, motivation, and cultural fit — relationship assessment requiring human judgment
Coordinates panel availability, candidate preferences, and room booking into optimal schedule
Aggregates interview scorecards into a single assessment with consensus and dissent highlighted
Makes hire/no-hire determination — permanently barred from AI by Regeneron policy, EEOC, and NYC LL144
Generates draft offer within approved comp band using market data and candidate expectations
Initiates vendor-integrated background verification and compliance checks
Sets up Day 1 readiness: systems access, training schedule, team introductions
Ranked candidate pipeline with briefs
Capacity from 20–30 to 40–50 reqs per TA Partner
HCP-spend compliance auditing
Scans 100% of HCP-payment transactions against Sunshine Act and AKS rules in real-time — vs human sampling of a fraction.
Pulls every expense and payment transaction from Oracle Fusion in real-time
Cross-references vendor IDs against NPI lookup database to identify healthcare professional recipients
Classifies each payment into Sunshine Act categories — meals, travel, consulting, research, education
Applies per-meal and per-event dollar thresholds per CMS reporting requirements
Screens payment patterns against Anti-Kickback Statute safe harbor provisions
Computes running annual spend per HCP for reporting threshold determination
Identifies statistical outliers — unusual frequency, amount, or vendor patterns
Detects multi-transaction patterns that individual checks miss — split payments, recurring gifts
Routes flagged transactions to appropriate compliance officer by severity and category
Reviews flagged transactions and makes final determination — humans adjudicate, system advises
Generates CMS Open Payments submission files with complete audit documentation
Records every screening decision with rationale for DOJ/FCA litigation defense
100% transaction screening + audit trail
Critical given active DOJ/FCA matter — transforms sample-based to full-coverage
Patient access hub coordinator
Integrates PA/BV + copay routing + adherence outreach into an end-to-end hub agent consuming 50–65% of the coordinator role across four hubs.
Receives and triages new patient cases across all four hub programs
Validates coverage status and plan details for each patient
Maps PA requirements by payer, plan, and indication
Selects correct submission pathway per payer rules
Compiles payer-specific evidence packages
Auto-fills payer-specific PA forms from evidence
Electronically submits to correct payer portal
Monitors submissions, triggers follow-up on overdue
Parses denial letters and generates appeal options
Selects appeal strategy based on clinical judgment
Routes patient to appropriate financial assistance program
Pre-screens patient against program criteria
Makes compliance-safe eligibility determination — active DOJ investigation
Sets up patient in correct program with copay card
Tracks refill patterns and flags discontinuation risk
Forecasts next refill date and identifies patients at risk of gap
Initiates outreach workflow when adherence score drops below threshold
Conducts patient calls requiring clinical advice or sensitive communication
Aggregates program metrics: approval rates, cycle times, abandonment rates
End-to-end patient access workflow
30–60 FTEs redeployed to exception management, appeal strategy, and compliance
Field reimbursement analyst
Formulary-change detection → payer-policy retrieval → territory impact → FRM briefs → denial pattern analysis. Unifies the payer intelligence pipeline.
Continuously scans formulary databases for status changes across all payers
Identifies material coverage changes — PA criteria, step therapy, tier moves, exclusions
Pulls updated policy documents and coverage criteria from payer portals
Calculates revenue impact of each formulary change by product and geography
Maps formulary changes to field territories and affected HCP practices
Produces prioritized alerts for field reimbursement managers by urgency and impact
Generates territory-specific briefs with talking points and payer-specific data
Analyzes patterns in claim denials by payer, reason code, and geography
Identifies systemic denial patterns vs one-off errors — feeds PA workflow improvements
Sets appeal approach for systemic denial patterns requiring payer negotiation
Logs all payer intelligence and field actions into CRM for territory tracking
Monitors competitor formulary positioning and market access moves
Aggregates field metrics: win rates, denial trends, coverage shifts
Real-time payer intelligence to field teams
15–30 FTEs consumed across formulary tracking, field reimbursement, and sales data
Formulary & coverage tracking
Monitors formulary status across all payers, detects coverage changes, quantifies revenue impact, and generates real-time field alerts.
Continuously polls formulary databases and payer portals for updates
Extracts updated coverage criteria, PA requirements, and step therapy rules from payer sites
Identifies material vs routine changes and flags new coverage restrictions
Separates changes requiring field action from administrative updates
Models financial impact of each change by product, geography, and patient volume
Maps each change to affected territories, zip codes, and prescriber practices
Ranks alerts by urgency: exclusion > new PA > tier change > minor update
Produces formatted alerts with context for field teams via CRM and email
Compares Regeneron formulary status vs competitors across key payers
Compiles coverage data for contract negotiation support
Pushes updated payer requirements to the PA submission pipeline (S1)
Continuous formulary intelligence
24/7 monitoring vs periodic manual review — never miss a coverage change
Sales pre-call planning
Daily pre-call briefs for Medical Specialists: territory data → opportunity scoring → HCP-specific brief. Assist layer, not FTE displacement.
Aggregates prescribing data, payer mix, and market share by territory
Identifies prescribing trends, new prescribers, and declining accounts
Ranks HCPs by conversion probability and revenue potential
Generates optimal daily call route factoring geography, priority, and access windows
Compiles individual HCP dossier: prescribing history, payer coverage, last interaction, publications
Maps each HCP's patient panel to current formulary status and PA requirements
Identifies relevant new clinical data or label updates for the HCP's specialty
Produces one-page brief per HCP with talking points, objection responses, and data highlights
Pre-populates CRM call notes from scheduled activities for rep to confirm/edit
Aggregates call metrics, conversion rates, and territory performance
Generates weekly territory summary with wins, losses, and priority shifts
Daily pre-call briefs by 7 AM
Throughput multiplier — every rep starts the day with HCP-specific intelligence
Gross-to-net calculations
Automates Medicaid rebate, managed care rebate, chargeback, 340B, PAP cost, and returns accruals. GTN is 30–50% of gross revenue.
Pulls transaction-level sales data by channel, customer, and contract
Maps each transaction to applicable rebate, chargeback, or discount rate
Computes accruals by channel — Medicaid, managed care, 340B, PAP, returns
Matches accrued amounts against actual claims received quarterly
Identifies material variances between accrued and actual for investigation
Evaluates adequacy of reserves based on historical patterns and pipeline data
Certifies reserve adequacy and accrual accuracy for financial statements — SOX requirement
Compiles supporting documentation for external audit review
Automated accrual calculations + reconciliation
Accrual accuracy directly impacts reported net revenue ($12.17B)
Financial close & reconciliation
Automates month-end: journals, reconciliations, intercompany eliminations, currency translation, variance analysis. Close from ~10 days to ~5.
Sequences all close tasks with dependencies and deadlines
Posts recurring journal entries — accruals, prepaid amortization, depreciation
Reconciles all balance sheet accounts against sub-ledgers and third-party statements
Processes intercompany eliminations across Ireland, UK, Japan, and US entities
Applies month-end exchange rates for currency translation of foreign subsidiaries
Computes period-over-period and budget-vs-actual variances by cost center
Drafts variance commentary for management reporting using API reasoning
Reviews and certifies financial statements — SOX attestation requirement
5-day financial close
Frees capacity from processing to analysis — controller reviews exceptions only
Omnichannel HCP campaigns
Automates HCP segmentation, content variant generation, campaign config, A/B testing, and performance reporting across all channels.
Segments HCPs by specialty, prescribing behavior, and engagement stage
Identifies prescribing patterns, brand affinity, and switching signals
Produces content variants tailored to each segment using approved claims
Submits all content variants through the MLR stack (S2) for compliance clearance
Sets up multi-channel campaign parameters — targeting, frequency, sequencing
Optimizes channel allocation (email, rep-triggered, digital, congress) by HCP preference
Determines optimal delivery timing based on HCP engagement patterns
Runs controlled tests on subject lines, content variants, and channel combinations
Monitors open rates, click-through, and downstream prescribing impact
Attributes prescribing changes to specific campaign touchpoints
Generates campaign ROI analysis by channel, segment, and brand
Personalized HCP engagement at scale
Content variants by specialty, indication, and engagement stage — all MLR-cleared
Finance operations center
Integrates AP + financial close + internal audit/SOX. Orchestration layer manages close sequencing and continuous control monitoring.
OCR extraction from invoices into Oracle Fusion
Automated purchase order matching
Three-way goods receipt validation
Sunshine Act compliance screening on every payment
Prevents double-payment across the invoice stream
Routes to correct approver per SOX matrix
Authorizes payments above SOX dollar threshold
Optimizes payment timing within vendor terms
Sequences month-end close tasks across all entities
Posts recurring entries and accruals
Reconciles balance sheet against sub-ledgers
Processes intercompany eliminations
Applies exchange rates for foreign subsidiaries
Computes period and budget variances
Drafts management commentary on variances
Certifies financial statements per SOX
Tests 100% of transactions against control criteria — replaces sampling
Identifies control failures and unusual patterns for investigation
Compiles audit-ready documentation for external auditors
Final sign-off on audit packages — external auditor reliance
Integrated finance operations with 100% control testing
Composed of S3 + S11 + Internal audit/SOX · 15–25 FTEs consumed
Commercial content engine
Full content generation + MLR + localization + DAM + deployment. Requires mature MLR-agent trust (Rung 3+).
Receives brand team brief with objectives, audience, and key messages
Checks brief alignment with current brand strategy and messaging hierarchy
Produces content variants for each channel, specialty, and indication
Validates every claim against approved labeling and claims matrix
Ensures risk/benefit prominence meets FDA requirements
Verifies all citations trace to approved sources
Produces review package highlighting issues for MLR committee
Three-person review — permanent FDA promotional compliance requirement
Validates all review comments addressed before publication
Publishes approved assets to digital asset management system with metadata
Selects target HCP segments for each approved content piece
Sets up campaign parameters across channels
Schedules delivery for maximum engagement
Distributes approved content through email, digital, rep-triggered, and congress channels
Monitors engagement and prescribing impact
Attributes revenue impact to content investments
Manages poster, booth, and symposium content timelines
Brief-to-deployment content pipeline
Composed of S2 + S12 + Congress/med-ed · 20–35 FTEs · Why Tier 3: needs MLR at Rung 3 first
Government pricing & GTN engine
Automates Medicaid Best Price, AMP, ASP, 340B calculations and CMS/HRSA submissions. Highest-value AND highest-risk.
Pulls transaction-level data by channel, customer, contract, and NDC
Maps each transaction to applicable government or commercial contract rate
Categorizes each sale into correct pricing channel for statutory calculations
Computes Best Price per CMS definition across all commercial transactions
Calculates Average Manufacturer Price per statutory methodology
Computes Average Sales Price for Medicare Part B reimbursement
Derives ceiling price for 340B covered entities per HRSA methodology
Validates pricing against April 2026 Most Favored Nation framework requirements
Computes government rebate and discount accruals by program
Matches accruals against actual government claims and chargebacks
Identifies material calculation variances for investigation
Evaluates adequacy of government pricing reserves
Certifies calculation accuracy for financial statements
Formats and validates government price reports for CMS submission
Prepares 340B ceiling price calculations for HRSA reporting
Certifies government pricing accuracy — FCA liability exceeds $100M if incorrect
Compiles government pricing audit trail for external review
Compliant government price calculations + submissions
Composed of Gov pricing + GTN (S10) + Contract analytics · 10–20 FTEs · Why Tier 3: MFN rules unstable
Three-phase rollout: prove in 90 days, scale by month 18
Each phase has explicit stage-gate criteria. Failure to meet gates extends the phase — do not proceed.
Deploy two beachhead stacks with mature vendor tech, existing data, and fast ROI. These fund the program politically and financially.
Build the Patient Access Hub factory — the largest automatable workforce across four hubs. Directly improves speed-to-therapy and protects revenue from prescription abandonment.
Deploy decision-layer factories requiring process-level integration — where the task→decision→process hierarchy creates value. Government pricing deferred until MFN rules stabilize.
From map to deployment — Phase 2 engagement
This analysis mapped 27 workflows at screening level and 4 at full decision-point depth. Phase 2 goes inside.
Framework, sources, and limitations
Framework: Intelligence Factory methodology
This analysis applies the Decision-Point Architecture framework from Code Is Speech: The New Fluency (Orr & de Jong, 2026). The methodology maps every decision point in a workflow, documents its inputs, judgment, output, volume, and consequence, and assigns each to the optimal intelligence layer through the Jagged Edge Trilemma: deterministic edge functions (fast, cheap, private), generative API calls (reasoning, novelty), or human operators (judgment, governance, relationships). Decision points are then chained into Agent Assembly Lines — pipelines of specialized agents with Guardian Agents validating quality at every handoff. Autonomy is governed by the Trust Escalation Ladder — graduated authority earned through demonstrated accuracy, not granted by executive mandate.
Sources
Regeneron Q2 2026 earnings release and call transcript · 2025 10-K annual report · regeneron.com (About, Careers, Leadership, Medicines, Pipeline) · Regeneron Position Statement on Responsible Use of AI (July 2025) · Job postings (regeneron.com/careers, LinkedIn, Glassdoor) · Revelio Labs workforce composition estimates · Peer disclosures (Sanofi plai, Eli Lilly/Yseop, Veeva Falcon MLR, Develop Health Calibrate, Pfizer Charlie) · Gartner agentic AI research · Industry workflow standards (AMCP, FDA promotional guidance, NPDES, SOX, AKS/FCA).
Outside-in limitations
This is an outside-in analysis: exact headcounts by function, field-force size, hub call volumes, and internal system configurations are not publicly disclosed. FTE and dollar estimates are directional inferences from peer benchmarks and Regeneron's disclosed SG&A ($2.70B GAAP), not internal data. Peer ROI figures (Veeva "70%+," Sanofi "$300M," Lilly "53%," Develop Health "80–85%") come from vendor or company communications and should be treated as directional, best-case claims. Gartner warns "over 40% of agentic AI projects will be canceled by the end of 2027" — execution risk is real.
What internal data would sharpen this analysis
SOPs and approval matrices for each priority workflow · Hub program staffing models and call volumes · Veeva Vault PromoMats configuration and approved claims matrix · PA approval/denial rates by payer and indication · Prescription abandonment rates during PA · Oracle Fusion ERP configuration details · Current automation baseline in each department · Sanofi's role in Dupixent MyWay operations · Internal AI Advisory Committee evaluation criteria.
With this data, each of the 23 screening-level workflows could be elevated to full Decision-Point Architecture depth — producing complete Trilemma assignments, agent assembly line designs, guardian agent specifications, and trust escalation ladders. That is the natural second phase of this engagement.